STOCK TITAN

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has announced the presentation of preclinical data for two internally developed cancer therapies at the AACR Annual Meeting 2025 in Chicago. The company will showcase:

1. ZL-6201: A novel antibody-drug conjugate (ADC) targeting LRRC15, which is overexpressed in various mesenchymal tumors including sarcoma, glioblastoma, and melanoma. This potential first-in-class treatment will be presented by Dr. Bing Wan on April 29, 2025.

2. ZL-1222: A next-generation PD-1-targeted IL-12 immunocytokine therapy designed to combine potent antitumor activity with improved systemic safety. Dr. Linda Liu will present this late-breaking research on April 28, 2025.

These developments align with Zai Lab's strategy for their internally developed global oncology pipeline, targeting multiple cancer types that remain challenging to treat with current standard-of-care therapies.

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) ha annunciato la presentazione di dati preclinici per due terapie oncologiche sviluppate internamente durante il AACR Annual Meeting 2025 a Chicago. L'azienda presenterà:

1. ZL-6201: Un nuovo coniugato anticorpo-farmaco (ADC) che colpisce LRRC15, sovraespresso in vari tumori mesenchimali tra cui sarcoma, glioblastoma e melanoma. Questo potenziale trattamento di prima classe sarà presentato dal Dr. Bing Wan il 29 aprile 2025.

2. ZL-1222: Una terapia immunocitochinica di nuova generazione mirata a PD-1, progettata per combinare una potente attività antitumorale con una maggiore sicurezza sistemica. La Dr.ssa Linda Liu presenterà questa ricerca innovativa il 28 aprile 2025.

Questi sviluppi sono in linea con la strategia di Zai Lab per il loro pipeline globale di oncologia sviluppato internamente, mirato a diversi tipi di cancro che rimangono difficili da trattare con le attuali terapie standard.

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) ha anunciado la presentación de datos preclínicos para dos terapias contra el cáncer desarrolladas internamente en el AACR Annual Meeting 2025 en Chicago. La empresa mostrará:

1. ZL-6201: Un nuevo conjugado de anticuerpo-fármaco (ADC) que se dirige a LRRC15, que está sobreexpresado en varios tumores mesenquimatosos, incluidos sarcoma, glioblastoma y melanoma. Este tratamiento potencial de primera clase será presentado por el Dr. Bing Wan el 29 de abril de 2025.

2. ZL-1222: Una terapia inmunocitoquina de nueva generación dirigida a PD-1, diseñada para combinar una potente actividad antitumoral con una mejor seguridad sistémica. La Dra. Linda Liu presentará esta investigación de última hora el 28 de abril de 2025.

Estos desarrollos están alineados con la estrategia de Zai Lab para su pipeline global de oncología desarrollado internamente, dirigido a múltiples tipos de cáncer que siguen siendo difíciles de tratar con las terapias estándar actuales.

자이랩 (NASDAQ: ZLAB; HKEX: 9688)은 시카고에서 열리는 AACR 연례 회의 2025에서 내부 개발한 두 가지 암 치료법에 대한 전임상 데이터를 발표한다고 발표했습니다. 회사는 다음을 선보일 예정입니다:

1. ZL-6201: 다양한 간질종양(육종, 신경교종, 흑색종 등)에서 과발현되는 LRRC15를 표적으로 하는 새로운 항체-약물 접합체(ADC). 이 잠재적인 최초의 치료법은 2025년 4월 29일 Bing Wan 박사에 의해 발표될 것입니다.

2. ZL-1222: 강력한 항종양 활성을 개선된 전신 안전성과 결합하도록 설계된 차세대 PD-1 표적 IL-12 면역사이토카인 치료법. Linda Liu 박사가 이 최신 연구를 2025년 4월 28일에 발표할 것입니다.

이러한 개발은 현재 표준 치료법으로 치료하기 어려운 여러 가지 암 유형을 목표로 하는 자이랩의 내부 개발 글로벌 종양학 파이프라인 전략과 일치합니다.

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) a annoncé la présentation de données précliniques pour deux thérapies contre le cancer développées en interne lors de la AACR Annual Meeting 2025 à Chicago. L'entreprise présentera :

1. ZL-6201: Un nouvel agent conjugué anticorps-médicament (ADC) ciblant LRRC15, qui est surexprimé dans divers tumeurs mésenchymateuses, y compris le sarcome, le glioblastome et le mélanome. Ce traitement potentiel de première classe sera présenté par le Dr Bing Wan le 29 avril 2025.

2. ZL-1222: Une thérapie immunocytokine de nouvelle génération ciblant le PD-1, conçue pour combiner une activité antitumorale puissante avec une sécurité systémique améliorée. La Dr Linda Liu présentera cette recherche de dernière minute le 28 avril 2025.

Ces développements s'inscrivent dans la stratégie de Zai Lab pour son pipeline mondial en oncologie développé en interne, visant plusieurs types de cancer qui restent difficiles à traiter avec les thérapies standards actuelles.

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) hat die Präsentation von präklinischen Daten für zwei intern entwickelte Krebstherapien auf dem AACR Annual Meeting 2025 in Chicago angekündigt. Das Unternehmen wird Folgendes präsentieren:

1. ZL-6201: Ein neuartiger Antikörper-Wirkstoff-Konjugat (ADC), der LRRC15 angreift, das in verschiedenen mesenchymalen Tumoren wie Sarkom, Glioblastom und Melanom überexprimiert ist. Diese potenzielle Therapie der ersten Klasse wird am 29. April 2025 von Dr. Bing Wan vorgestellt.

2. ZL-1222: Eine Immunzytokintherapie der nächsten Generation, die auf PD-1 abzielt und darauf ausgelegt ist, eine starke antitumorale Wirkung mit verbesserter systemischer Sicherheit zu kombinieren. Dr. Linda Liu wird diese bahnbrechende Forschung am 28. April 2025 präsentieren.

Diese Entwicklungen stehen im Einklang mit der Strategie von Zai Lab für ihre intern entwickelte globale Onkologie-Pipeline, die sich auf mehrere Krebsarten konzentriert, die mit den derzeitigen Standardtherapien weiterhin schwer zu behandeln sind.

Positive
  • None.
Negative
  • None.
  • Poster presentation will highlight the potential of ZL-6201 as an innovative antibody-drug conjugate (ADC) for the treatment of sarcoma and other leucine-rich repeat-containing protein 15 (LRRC15)-positive solid tumors
  • Late-breaking poster presentation will summarize data from preclinical evaluation of ZL-1222, a promising next-generation interleukin-12 (IL-12) immunocytokine therapy for the treatment of various cancers

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30, 2025 in Chicago, Illinois.

“Aligned with our strategy for our internally developed global oncology pipeline, ZL-6201 and ZL-1222 are promising investigational compounds with the potential to address multiple cancer types, including several that remain challenging to treat with current standard-of-care therapies,” said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab.

LRRC15 is a type I transmembrane protein and an appealing target for cancer therapy because it is overexpressed in various mesenchymal tumors, such as sarcoma, glioblastoma and melanoma. Zai Lab is evaluating ZL-6201 as a potential first-in-class LRRC15 ADC targeting multiple solid tumors.

Interleukin-12 treatments have demonstrated potential to offer therapeutic benefit across a range of cancer types; however, narrow therapeutic windows and toxicity concerns have limited the benefit of this therapeutic class. Zai Lab is evaluating ZL-1222 as a potential next-generation PD-1-targeted IL-12 immunocytokine for cancer immunotherapy across a variety of indications, potentially combining potent antitumor activity with improved systemic safety.

Details regarding the Zai Lab poster presentations at AACR 2025 are as follows:

Title: Discovery and characterization of a novel LRRC15-targeting antibody-drug conjugate (ADC) for the treatment of solid tumors
Presenter: Bing Wan, Ph.D., Executive Director, Biology, Zai Lab
Session Title: New and Emerging Cancer Drug Targets
Date/Time: Tuesday, April 29, 2025, from 9:00 a.m. - 12:00 p.m. CT
Location: McCormick Place Convention Center, Poster Section 17
Poster Board Number: 23
Published Abstract Number: 4266

Title: Cis-delivery of a potency-reduced IL-12 via an anti-PD-1 single-chain antibody exhibits potent anti-tumor activity
Presenter: Linda Liu, Ph.D., Senior Vice President, Biologics Discovery, Zai Lab
Session Title: Late-Breaking Research: Clinical Research 1
Date/Time: Monday, April 28, 2025, from 2:00 p.m. - 5:00 p.m. CT
Location: McCormick Place Convention Center, Poster Section 53
Poster Board Number: 1
Publish Abstract Number: LB2024

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global.

Zai Lab Forward-Looking Statements

This press release contains forward-looking statements relating to our future expectations, plans, and prospects, for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing ZL-6201 and ZL-1222, the potential benefits of ZL-6201 and ZL-1222, and the potential treatment of solid tumors. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Our SEC filings can be found on our website at www.zailaboratory.com and on the SEC’s website at www.SEC.gov.

Investor Relations:

Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com



Media:

Shaun Maccoun / Xiaoyu Chen

+1 (857) 270-8854 / +86 185 0015 5011

shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Source: Zai Lab Limited

FAQ

What are the two new cancer therapies ZLAB is presenting at AACR 2025?

ZLAB is presenting ZL-6201, an LRRC15-targeting antibody-drug conjugate for solid tumors, and ZL-1222, a PD-1-targeted IL-12 immunocytokine therapy for cancer treatment.

Which types of cancer does ZLAB's ZL-6201 target?

ZL-6201 targets cancers with LRRC15 overexpression, including sarcoma, glioblastoma, and melanoma.

When and where will ZLAB present their new cancer therapy data?

The data will be presented at the AACR Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, Illinois.

How does ZLAB's ZL-1222 improve upon current IL-12 treatments?

ZL-1222 is designed to combine potent antitumor activity with improved systemic safety, addressing the toxicity concerns that have previous IL-12 treatments.

Who are the key presenters for ZLAB's cancer therapy research at AACR 2025?

Dr. Bing Wan will present ZL-6201 research on April 29, and Dr. Linda Liu will present ZL-1222 research on April 28, 2025.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Stock Data

3.99B
106.50M
1.47%
53.9%
7.23%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI